The Mechanism of Unresponsiveness to Circulating Tumor
Immunity to tumor Ags in patients is typically weak and not therapeutic. We have identified a new mechanism by which potentially immunogenic glycoprotein tumor Ags, such as MUC1, fail to stimulate strong immune responses. MUC1 is a heavily glycosylated membrane protein that is also present in soluble form in sera and ascites of cancer patients. We show that this soluble protein is readily taken up by dendritic cells (DC), but is not transported to late endosomes or MHC class II compartments for processing and binding to class II MHC. MUC1 uptake is mediated by the mannose receptor, and the protein is then retained long term in early endosomes without degradation. Long-term retention of MUC1 does not interfere with the ability of DC to process and present other Ags. We also demonstrate inhibited processing of another important glycoprotein tumor Ag, HER-2/neu. This may, therefore, be a frequent obstacle to presentation of tumor Ags and an important consideration in the design of cancer vaccines. It should be possible to overcome this obstacle by providing DC with a form of tumor Ag that can be better processed. For MUC1 we show that a 140-aa-long synthetic peptide is very efficiently processed by DC. The Journal of Immunology, 2000, 165: 3730 -3741. O ne of the major goals of tumor immunology has been to find ways to enhance T cell responses to tumor Ags and incorporate these findings in the design of tumor-specific vaccines (1) (2) (3) (4) (5) (6) . Knowledge of how tumor Ags are processed and presented by APCs is critical for understanding the initiation of immune responses against tumors and for the development of efficacious vaccines. Many tumor-specific Ags identified to date have been characterized as proteins expressed differentially by tumor cells, which distinguishes them immunologically from normal cells. This differential expression may be the result of mutations in normal proteins, overexpression of normal proteins, or changes in the intracellular localization (2, 4) .
Cancer patients develop immune responses to many tumor Ags, but these responses are typically weak and not therapeutic. CTL, if found, are present at low frequency, and Ab responses are characterized by low titers. The poor quality of T cell responses to tumor Ags in patients can be attributed to several factors that can vary with the type of the tumor or the nature of the tumor Ag. Tumors themselves are not good APCs (7, 8) , and in some instances have been shown to induce T cell anergy (9 -11) . Similarly, many identified tumor Ags are differentially expressed self proteins to which high affinity T cells may have been eliminated (12, 13) . We report here another mechanism by which cancer patients' T cells are kept unresponsive to an abundant circulating tumor Ag MUC1 by the inability of APCs to efficiently process this potentially immunogenic tumor protein.
Even though it has been identified as a tumor Ag, MUC1 is also found on the apical surfaces of normal ductal epithelial cells (14) . It consists of numerous tandemly repeated 20-aa segments (up to 200/molecule), each of which contains five sites for O-linked glycosylation. When expressed on normal cells, MUC1 is extensively glycosylated at all sites with long, branched, O-linked oligosaccharide chains. Furthermore, the extracellular membrane-proximal domain (preceding the tandem repeat region) is glycosylated at five sites with N-linked carbohydrates. This heavily glycosylated protein is cleaved off the epithelial cell surface and becomes a component of ductal secretions. MUC1 expression on tumor cells is much higher than that on normal cells and it is not polarized. The glycosylation pattern also changes to linear rather than branched oligosaccharides and to much shorter chains added to fewer glycosylation sites (15) . These tumor-specific forms of MUC1 are also cleaved off the tumor cells, drain to regional lymph nodes and enter the peripheral circulation. They can be purified from sera and ascites fluid of patients with late stage tumors.
Immune responses against MUC1 found in cancer patients are characterized by a low frequency of CTL and a low titer of Ab of the IgM isotype (16 -21) . The CTL responses consist of a low frequency of class I MHC-restricted CTL and a low frequency of MHC-unrestricted CTL (16 -24) . No evidence has been reported of in vivo elicited MUC1-specific Th activity. We recently reported that MHC class II-restricted, CD4
ϩ Th cells can be primed in vitro to recognize MUC1, but only if synthetic, completely unglycosylated, MUC1 protein core peptide is used as Ag to load dendritic cells (DC) 5 (25) . Tumor-derived MUC1 glycosylated with short linear carbohydrates, isolated from patients' sera or ascites, failed to prime Th cells. Moreover, in vitro priming of class I-restricted CTL by DC loaded with tumor-derived MUC1 was also much less efficient than priming with DC loaded with the synthetic MUC1 peptide (26) . Others have also shown that in mice immunization with the human MUC1 (which shares little homology with mouse MUC1) elicits immune responses only when unglycosylated protein is used (27) (28) (29) .
In this paper we examine the uptake and processing of two forms of MUC1, the circulating form of MUC1 with tumor-specific glycosylation that is available to patient APC in vivo, and the unglycosylated synthetic polypeptide (140 aa long) composed of seven MUC1 tandem repeats that can be provided through vaccination. By directly fluorescently labeling each protein, we examined by flow cytometry the uptake of these proteins by DC and followed them intracellularly by confocal microscopy. We show that each protein was readily internalized by DC, but that the transport of tumor MUC1 and that of synthetic MUC1 were completely divergent. The glycosylated tumor MUC remained stranded in the early endosomes, while the synthetic peptide was transported to late endosomes for processing. We also explored the mechanism involved in the internalization of both forms of MUC1 by DC and what effect (if any) uptake of these proteins had on their ability to process and present other Ags. Furthermore, to address the possibility that inhibited processing of glycosylated proteins might be a common phenomenon, we examined uptake by DC and intracellular transport of another glycoprotein tumor Ag, HER-2/neu. Like MUC1, HER-2/neu fails to elicit Th cells in vivo, while vaccination with short synthetic peptides derived from this molecule elicits strong helper responses (30) . We show that its transport is also blocked at early endosomes.
The strategy we determined to be useful for circumventing inefficient processing of MUC1 was to provide APCs with an unglycosylated form of the Ag, which we show can be efficiently taken up and processed by DC. These latest studies explain our previously reported observations that tumor MUC1 is not able to elicit class Iand class II-restricted T cell responses, but that these responses are efficiently elicited with a synthetic MUC1 peptide (25, 26) .
Materials and Methods

Antigens
Tumor-derived MUC1 (glycosylated form) was purified from ascites fluid pooled from several patients with metastatic breast or pancreatic tumors by density gradient centrifugation (31), followed by immunoaffinity chromatography using MUC1-specific Ab 3C6 (gift from Dr. Jo Hilgers, Free University, Amsterdam, The Netherlands). This form of MUC1 (ϳ200 kDa) is cleaved off the tumor cell surface and does not contain the transmembrane and the cytoplasmic domain. The recombinant, baculovirusderived form of MUC1 contains 22 tandem repeats as well as the transmembrane and cytoplasmic domains (31) . The synthetic 140-mer peptide representing seven repeats of the MUC1 protein sequence GVTSAPDTR-PAPGSTAPPAH was synthesized at the Peptide Synthesis Facility of the Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine (Pittsburgh, PA). All forms of MUC1 were directly conjugated to either Cy3 or Cy5 fluorescent dye according to the manufacturer's instructions (Amersham Pharmacia Biotech, Piscataway, NJ). FITC-conjugated mannosylated BSA was purchased from Sigma (St. Louis, MO). Human HER-2/neu extracellular domain (ECD) was a gift from Dr. Tom Vedvick (Corixa, Seattle, WA). It was produced as a secreted protein in a mammalian L cell expression system by cloning HER-2/neu cDNA into the plasmid vector pMTK-bGH-C. The secreted protein was extensively purified through several standard chromatographic methods. Following purification, the protein preparation showed only one peak on reverse phase HPLC and a single band of 110 kDa on Coomassiestained gel. CMV lysate and mock cell lysates were gifts from Dr. Penelope Morel (University of Pittsburgh School of Medicine). The CMV lysate was generated by sonication of MRC5 human fetal lung fibroblast cells infected with the AD169 strain of CMV following 1 wk of infection at a multiplicity of infection of 10:1. Mock lysate was generated under the same conditions from uninfected fibroblasts.
Antibodies
Purified, mouse anti-human transferrin receptor (CD71) was purchased from Immunotech, (Westbrooke, ME). PE-conjugated mouse anti-human LAMP-1, HLA-DM, and mouse anti-human mannose receptor (blocking Ab clone 19 and PE-labeled marker Ab) were purchased from PharMingen (San Diego, CA). PE-conjugated mouse anti-human HLA-DR, CD14, and CD86 were purchased from Becton Dickinson (San Jose, CA). Alexa-546-conjugated goat anti-mouse IgG was purchased from Molecular Probes (Eugene, OR).
Generation of DC
Monocyte-derived DC were generated in vitro according to a previously described protocol (32) . Following removal of RBC from a leukopheresis product from a healthy donor, PBMC were plated in T-75 flasks for adherence for 2 h. After 2 h, nonadherent cells were removed by gentle washing with warm medium. The remaining loosely adherent cells were cultured for 8 days in serum-free AIM V medium (Life Technologies, Gaithersburg, MD) containing GM-CSF (10 ng/ml; Schering-Plough, Kenilworth, NJ) and IL-4 (25 ng/ml; Schering-Plough). The DC cultures were fed with additional medium and cytokines on days 4 and 6 of culture. DC were then harvested and used in the uptake and trafficking experiments without further purification. The purity of DC in the cultures at this time point was Ͼ60% as measured by flow cytometry for DC markers.
Ag uptake/inhibition of uptake assays DC were harvested, washed, and resuspended in serum-free AIMV medium at a concentration of 2.5 ϫ 10 6 /ml. DC were then added to sterile 4-ml polypropylene pop-capped tubes (Falcon, Becton Dickinson, Franklin Lakes, NJ) at 100 l/tube (2.5 ϫ 10 5 /tube). Fluorescently labeled proteins were added to the tubes at a final concentration of 10 g/ml. The DC were allowed to internalize the protein at 37°C for various times. The cells were then washed three times with cold medium and fixed with 1% paraformaldehyde. Uptake of the proteins was quantitated by flow cytometric analysis using a Becton Dickinson FACScalibur and CellQuest software. To exclude contaminating non-DC, analysis gates were set on cells with the highest forward scatter. These cells typically represented Ͼ60% of the total cell population.
Cytochalasin D (used at 10 M), wortmannin (used at 100 nM), LY294002 (used at 50 M), and mannan (used at 200 g/ml) were purchased from Sigma. Sucrose (used at 500 M) was purchased from Life Technologies/BRL (Grand Island, NY). Inhibition assays were performed by pretreating the DC for 30 min with an inhibitor followed by the addition of fluorescently labeled Ag. Unless otherwise indicated, the DC were allowed to take up the labeled proteins for 1 h at 37°C in the presence of inhibitor. Following this uptake period, the DC were washed and fixed with 1% paraformaldehyde, and the amount of internalized fluorescence was quantitated by flow cytometry. The percent inhibition was calculated by first subtracting the mean fluorescence intensity (MFI) of DC incubated with labeled protein on ice from both inhibitor-treated and untreated samples. These normalized numbers were then used in this equation: % uptake ϭ [((MFI of untreated DC ϩ protein) Ϫ (MFI of inhibitor-treated DC ϩ protein))/(MFI of untreated DC ϩ protein)] ϫ 100%; % inhibition ϭ 100 Ϫ % uptake.
Competition assays to determine cell surface binding of Ags were performed in a similar manner as those described above with the following modifications: binding was conducted at 4°C to eliminate internalization, and competitor used in these assays was a 10-fold excess of the same protein, unlabeled, which was added to the DC for 15 min before the addition of labeled protein. Competitor was maintained throughout the 30-min binding period. The percent inhibition of binding was calculated as described above.
Pulse-chase analyses for retention of MUC1 were performed by allowing the DC to take up Ag for 1 h at 37°C, washing extensively, then maintaining the DC at 37°C for the indicated periods of chase to allow processing of Ag. DC, which were fixed immediately following the pulse period, were used as a positive control and were counted as 100%. The MFIs of chased samples were then divided by the MFI of positive control DC to calculate the percentage of retained fluorescence.
8 DC at a 20 g/ml final concentration in 1 ml of AIM V medium for 15 min or 2 h as indicated. The cells were then washed to remove excess Ag, pelleted, and fixed in 2.5% glutaraldehyde in PBS. The 1-mm 3 pellets were postfixed in 1% OsO 4 and 1% K 3 Fe(CN) 6 for 1 h. After three washes the pellet was dehydrated through a graded series of 30 -100% ethanol and 100% propylene polypropylene oxide and infiltrated in a 1/1 mixture of propylene oxide/Polybed 812 epoxy resin (Polysciences, Warrington, PA) for 1 h. After several changes of 100% resin over 24 h, cells were embedded in molds and cured at 37°C overnight, followed by additional hardening at 65°C for 2 more days. Ultrathin (60-nm) sections were collected 200-mesh copper grids and stained with 2% uranyl acetate in 50% methanol for 10 min, followed by 1% lead citrate for 7 min. Sections were viewed with a CX100 transmission electron microscope (Jeol, Peabody, MA) at 60 or 80 kV.
Confocal laser scanning microscopy
DC were harvested after 8 days of culture and plated on Lab-Tek chamber slides (Nalge Nunc, Naperville, IL) at a density of 5 ϫ 10 3 -10 4 DC/chamber and allowed to adhere for 2 h. DC were then washed with warm medium, and adherent DC were exogenously pulsed with 10 g/ml fluorescently labeled protein for the indicated time periods. Following uptake and processing, DC were fixed with 2% formaldehyde, permeabilized with 0.1% saponin, and counterstained with PE-labeled Abs to visualize intracellular compartments. To amplify the signal of the primary Abs and compensate for the bleaching of PE by the confocal laser, an Alexa-546-labeled goat anti-mouse IgG was used as a secondary Ab for staining. Following staining, DC were fixed a second time with 1% paraformaldehyde, the chambers were removed, and the slides were mounted using Vectashield mounting medium (Vector, Burlingame, CA) and analyzed by confocal laser scanning microscopy. For these analyses, we used a Leica TCS NT confocal LSM microscope (Rockleigh, NJ); images were collected using the ϫ40 objective. Micrographs shown are projections of serial sections scanning the majority of the cell. Each image is representative of at least 50 fields scanned, with an average of 10 cells/field; 0.5-m-thick optical sections (typically eight per cell) were simultaneously scanned for excitation of Alexa-546 and Cy5. Cy5 is a far red fluorescing dye to which any color can be assigned by computer.
CMV-specific T cell proliferation
DC were generated from a CMV-seropositive normal donor for 8 days in culture with GM-CSF and IL-4, as described above. The cells were harvested and plated in 96-well plates at a density of 10 4 DC/well. They were pulsed with either glycosylated tumor MUC1 (100 g/ml), keyhole limpet hemocyanin (KLH; 100 g/ml) or no Ag for 1 h. A lysate of CMV-infected cells or mock lysate (described above) was then added to the DC in increasing doses in 96-well plates. Autochthonous T cells were added to the plates at a concentration of 10 T cells/DC. These cultures were maintained for 4 days, and proliferation was measured in a standard tritiated thymidine incorporation assay.
Detection of recycled glycosylated tumor MUC1
Immature day 8 GM-CSF/IL-4 human DC were pulsed at 4 or 37°C with the fluorescent Ag (as described above) for 30 min. The uptake was stopped with extensive washes in cold PBS, and the cells were subsequently treated with 0.15 M glycine for 30 min at 4°C. As controls, untreated cells were similarly handled. After the acid treatment, the cells were extensively washed and returned to normal medium conditions (200-l final volume) and chased for 90 min under the temperature conditions of the pulse step (4 or 37°C, respectively). At the end of the chase period the cells were centrifuged, and 100 l of the supernatant was used for protein detection by ELISA. The pelleted cells were analyzed for retention of fluorescence by FACS.
MUC1 detection in the supernatant was performed using an Ab-sandwich ELISA. Immulon 4 (Dynex Technologies, Chantilly, VA) ELISA plates were coated overnight at 4°C with a mixture of two anti-MUC1 mAbs, Ma552 (34) and HMPV (35) , at a final concentration of 10 g/ml in a volume of 50 l/well. After extensive washes and blocking in Tween-20 (0.05%) blocking buffer, 30 l of the saved supernatant was added to the coated wells in triplicate and incubated at room temperature for 2 h. The same mixture of Abs was used to detect the bound Ag. The reaction was developed by adding a secondary anti-mouse IgG, peroxidase conjugated (Sigma), in the presence of o-phenylenediamine substrate solution (1 mg o-phenylenediamine/ml of 0.05 M citrate buffer, pH 4.0, and 0.05% H 2 O 2 ; Sigma). The reaction was stopped at 20 min with 2.5 M H 2 SO 4 . Absorbencies were read at 490 nm using the automatic MRX Revelation plate reader (Dynex Technologies) and Revelation 4.21 software to calculate means and SDs. Data were plotted using Cricket Graph software (Computer Associates International, Islandia, NY).
Results
Uptake of MUC1 by DC
We considered that one potential explanation for the inability of DC to prime MUC1-specific T cells when loaded with the glycosylated tumor form of MUC1 (25, 26) could be that DC were simply unable to take up this protein. To analyze and quantitate the uptake of this form of MUC1 by DC and to compare it to the uptake of unglycosylated synthetic peptide, we directly labeled the two forms with fluorescent dyes, fed them to 8-day-old DC in vitro, and monitored by flow cytometry the increase in DC fluorescence intensity over time. The day 8 DC expressed high levels of class II MHC, mannose receptor, and costimulatory molecules and had lost CD14 expression (data not shown). These cells were not fully mature DC, however, as they were still able to take up large amounts of Ag through macropinocytosis and receptor-mediated endocytosis and contained numerous intracellular MHC class II compartments.
Depicted in Fig. 1 is the uptake of two forms of MUC1, 140-mer synthetic peptide and glycosylated tumor MUC1. The histograms (Fig. 1, A and B) show uptake of each fluorescently (Cy5)-labeled protein at 37°C compared with the amount of surface-bound protein at 4°C (on ice). Both forms of MUC1 were efficiently taken up by DC after 30 min and in even greater amount after 2 h. This increase in fluorescence intensity was due to internalization of both forms, as can be seen in the electron micrographs. Glycosylated tumor MUC1 can be seen at the cell surface in a clathrin-coated pit (Fig. 1C) as well as inside the cell in a small endocytic vesicle (Fig. 1D) . The MUC1 peptide is found predominantly in large, fluid-filled, pinocytic vesicles (Fig. 1E ). Both forms were directly conjugated to 20-nm gold beads.
Trafficking of MUC1 within DC
Peptide epitopes presented by class II MHC are typically derived from proteins acquired by APCs from exogenous sources (36 -39) . Following internalization, proteins are transported through a series of early and late endosomes or lysosomes in which acidification and degradative activity progressively intensify (37) . These vesicles can be identified microscopically using fluorescently labeled Abs against specific resident proteins, such as transferrin receptor, a marker of early endosomes, and LAMP-1, a lysosomal marker. Endocytic vesicles with degraded protein fragments fuse with class II MHC-rich MIIC vesicles (38) , where binding of peptides to class II molecules is facilitated by HLA-DM (39, 40) . Both HLA-DM and HLA-DR are markers of the MIIC compartments.
We considered that the lack of presentation of glycosylated tumor MUC1 by class II MHC might be the result of this form not being properly transported to late endosomal and MIIC Ag-processing compartments. DC cultured on chamber slides were simultaneously fed fluorescently labeled tumor MUC1 and synthetic MUC1. After 2 h to allow for both uptake and processing to take place, the DC were fixed, permeabilized, and stained with an Ab against HLA-DR. The slides were then examined by confocal laser scanning microscopy. The results of this experiment are depicted in the first four panels of The three-color overlay (D) shows almost complete colocalization (in yellow) of the peptide and HLA-DR and no colocalization of glycosylated MUC1 (in blue) with HLA-DR. These results clearly show that following uptake, glycosylated tumor MUC1 is not transported to the MIIC compartments where processing and binding to class II MHC would occur. In contrast, the same DC transports the unglycosylated MUC1 synthetic peptide to these compartments very efficiently. This difference is in the strong correlation with our published functional studies, which demonstrated that only the synthetic peptide form of MUC1 was presented to T cells, while the glycosylated tumor form was not (25, 26) .
To address the possibility that in addition to the difference in glycosylation, the difference in the size of the molecule could account for this, we examined the trafficking of the recombinant form of MUC1. This molecule is equivalent in size to the glycosylated tumor MUC1, but lacks both O-linked and N-linked carbohydrates (data not shown). As shown in Fig. 2E , this form of MUC1 colocalizes with HLA-DR in the same way as the unglycosylated peptide. Within 2 h after uptake, all the recombinant MUC1 was found in a compartment rich in HLA-DR. These data suggest that glycosylation rather than protein size is the determining factor in the retention of tumor MUC1 in early endosomes.
In a more comprehensive microscopic analysis, DC were exogenously pulsed with Cy5-labeled glycosylated tumor MUC1 (indicated in green), fixed, permeabilized, and costained (red) with Abs against markers of either early or late endosomal compartments. As expected, glycosylated tumor MUC1 colocalized with the transferrin receptor (Fig. 2F) , a marker of early endosomes (37) , and the mannose receptor, present predominantly in early endosomes and less frequently in later endosomes and MIIC (41) . Colocalization with the mannose receptor was seen only in peripheral vesicles and was not present in the more perinuclear, mannose receptor-containing, later endosomes (Fig. 2G ). There was little or no colocalization with late endosomal markers HLA-DM (Fig. 2H) and LAMP1 (Fig. 2I) . 
Long-term retention of glycosylated MUC1 by DC
To address the fate of glycosylated MUC1 and the 140-mer peptide inside DC, we followed these proteins by confocal microscopy over a period of 24 h and quantitated by flow cytometry the amount of each form that was retained. For confocal analyses, DC were exogenously pulsed with either form of Cy5-labeled MUC1 (assigned a green color) and then chased for indicated times, when they were fixed, permeabilized, and stained with a PE-labeled anti-HLA-DR Ab (red). As in the previous micrographs, colocalization of green and red appears in yellow. The 140-mer peptide (Fig. 3,  upper panels) is trafficked to HLA-DR-rich compartments within 15 min after uptake, remains exclusively associated with perinuclear DR-rich endosomes at 2 h, and is difficult to detect at 24 h, probably due to almost complete degradation. In contrast, glycosylated tumor MUC1 (lower panels of Fig. 3 ) is retained in large vesicles adjacent to the plasma membrane, apparently undegraded even after 24 h following uptake. The appearance of some yellow color in this figure is a consequence of the way the images are displayed. The green MUC1 and red HLA-DR actually reside in different vesicles in separate planes, but some of these vesicles become superimposed when the images are shown as stacked projections. The images are displayed this way to enable visualization of the entire DC and to demonstrate the peripheral localization of glycosylated MUC1. We have also performed FACS analysis to evaluate loss of fluorescence over time and have found fluorescence retained only in DC loaded with the glycosylated MUC1. A high level of fluorescence was maintained even after 48 h and was not diminished after activation of DC through ligation of cell surface CD40 by soluble CD40 ligand trimer (data not shown).
Uptake and retention of glycosylated MUC1 by DC do not interfere with their processing and presentation of another Ag
Carbohydrate moieties have been shown to inhibit presentation of either Ags to which they are bound or of other Ags taken up by the same APC (42) . Because glycosylated tumor MUC1 is taken up and retained by APCs long term, we questioned whether this may inhibit the ability of these cells to process and present other Ags to class II-restricted Th cells. To address this question, we pretreated DC generated from a CMV-seropositive donor with 100 g/ml of glycosylated MUC1, control Ag KLH, or no Ag, before addition of CMV Ag, a whole cell lysate from CMV-infected fibroblasts. Autochthonous T cells were then added to the cultures, and the proliferative responses to CMV Ags were evaluated in a 4-day proliferation assay. T cells responded in a dose-dependent manner to the CMV lysate and had similar responses to this Ag in the presence of either excess MUC1 glycoprotein (10 times the amount used in the confocal studies) or KLH (Fig. 4) . 
Binding of glycosylated tumor MUC1 to DC is receptor mediated
DC internalize Ag through receptor-mediated endocytosis, phagocytosis, and macropinocytosis (43, 44) . The most efficient mechanisms for delivery of Ags to MIIC compartments for presentation via class II MHC are receptor-mediated endocytosis and macropinocytosis (45) (46) (47) . Thus, we compared the mechanisms responsible for uptake of the two forms of MUC1 by determining the binding specificity (if any) of either form to DC and using inhibitors of either the receptor-mediated endocytosis or macropinocytosis.
As a confirmation of the active endocytic uptake, preincubation of DC with cytochalasin D (48) for 30 min prior to addition of the Ag led to a dramatic (90%) inhibitory effect on uptake when the glycosylated tumor MUC1 was added for an additional 30 min, suggesting that active actin-based cytoskeletal rearrangements are required for the internalization of this molecular form (Fig. 5A) . The uptake inhibition of the synthetic peptide was only about 70% (Fig. 5B) , suggesting that although the majority of increased fluorescence is due to active uptake, this smaller molecular form may still be internalized through small pinocytic vesicles.
Receptor-mediated endocytosis, phagocytosis, and macropinocytosis are endocytic mechanisms thought to play the largest role in internalization by DC. To distinguish between the mechanisms directly involved in the uptake of the two molecular forms of MUC1 we performed a series of experiments using inhibitors of known specificities. LY294002 and wortmannin were chosen as inhibitors of macropinocytosis that act through inhibition of PI-3 FIGURE 4. Uptake and retention of glycosylated MUC1 by DC does not interfere with their ability to process and present other Ags. DC were generated, and T cells were isolated from a normal, CMV-seropositive donor. DC were harvested and prepulsed with 100 g/ml MUC1 or KLH as a control, then 10-fold dilutions of CMV lysate (or mock lysate as a control) were added to the DC for an additional hour. Autochthonous T cells were coincubated with the Ag-pulsed DC for 4 days, and proliferation was measured by 3 H incorporation. This result is representative of two independent experiments. kinase, an essential signal transduction molecule involved in membrane ruffling (49, 50) . We found that pretreatment of DC with these reagents only partially inhibited uptake of glycosylated tumor MUC1 (Table I ) while strongly inhibiting uptake of the 140-mer peptide. Sucrose (0.5 M), an inhibitor of receptor-mediated endocytosis that interferes with clathrin-coated pit formation (51), caused significant inhibition of the uptake of glycosylated form and had no effect on the synthetic peptide (data not shown). In addition, uptake of glycosylated tumor MUC1 is inhibitable by cold, unlabeled protein and shows a saturable uptake curve, whereas the synthetic peptide is uninhibitable by its own unlabeled control (data not shown). Taken together, the results of the above experiments correlated with the electron micrographs findings suggested that the uptake of glycosylated MUC1 by DC is regulated by a receptor-mediated mechanism and that internalization of the 140-mer peptide is primarily mediated through macropinocytosis.
Inhibitors of mannose receptor-mediated uptake inhibit uptake of glycosylated MUC1
Having determined that glycosylated MUC1 was taken up by DC through a receptor-mediated mechanism, we addressed the question of specifically which receptor was involved. One particularly efficient receptor expressed at high levels on DC (expression is highest on immature DC and drops as they mature) is the mannose receptor (MR). This receptor has high specific affinity for both mannose and fucose residues. Furthermore, the MR has been characterized as a pattern recognition receptor mediating the uptake of many microbial products, the best defined of these being lipoarabinomannan, from mycobacteria (41, 52) . The mannose and fucose residues for which mannose receptor is specific are present on glycosylated tumor MUC1, 6 raising the possibility that MR may mediate the uptake of this molecule. To address the binding of MUC1 to MR, we used mannan (polymannose), which competes for binding to MR, and a blocking mAb specific for MR. DC were preincubated with either inhibitor for 10 min before the addition of labeled MUC1 (glycosylated tumor protein or peptide). Mannosylated BSA was included as a positive control. Following a 1-h uptake period at 37°C, DC were washed, fixed, and analyzed by flow cytometry. Uptake of glycosylated MUC1 was significantly inhibited both by excess mannan and by the blocking Ab against the MR (Table II) . Both these reagents also strongly blocked uptake of mannosylated BSA, but had little or no inhibitory effect on uptake of the 140-mer peptide. These findings strongly suggest that uptake of glycosylated MUC1 by DC is in large part mediated by the MR. We cannot rule out the contribution of macropinocytosis or another receptor, however, which may account for the inability of MR blockers to completely inhibit MUC1 uptake.
Processing of glycosylated MUC1 is enhanced in the presence of excess mannose
Due to numerous glycosylated tandem repeats on each molecule, MUC1 uptake via MR probably results in massive cross-linking of the receptors. The high avidity of this interaction may not allow the uncoupling of the MR from the MUC1 ligand that is supposed to occur in endosomal sorting compartments or CURL (compartments for uncoupling of receptors and ligands) (53) (54) (55) . CURL are specialized endosomes where receptors disengage from ligands and are selectively removed and concentrated in tubular extensions that are then recycled to the plasma membrane. CURL vesicles containing concentrated free ligand are transported to lysosomes where ligand is degraded. The extended colocalization of glycosylated MUC1 with MR in early endosomes suggests that the receptors are unable to dissociate from the ligand and leave the endosomes; therefore, further progression down the endocytic pathway is halted. To address this possibility, we allowed the DC to internalize MUC1 protein for 1 h, extensively washed the cells, then added excess mannose to compete with MUC1 for the MR in the early endosomes. We postulated that this may facilitate MUC1 dissociation from the MR and release the block on its further transport. In the absence of free mannose, 44% of glycosylated MUC1 was retained after a 24-h chase period. With the addition of mannose to the chase, however, the amount of retained MUC1 was substantially reduced at 24 h, and this reduction was dependent on the dose of mannose (Fig. 6) . The greatest decrease in retained fluorescence (to 18%, a level similar to that of the control protein, mannosylated BSA) resulted from the addition of 50 M mannose. This dose of mannose was not toxic to the DC, and there was no effect on the processing of the 140-mer peptide and only a slight reduction in the retention of mannosylated BSA. We interpret these results to mean that mannose, which diffuses into the cell and early endosomes due to its small size, competes with MUC1 for binding to MR. The loss of fluorescence may indicate that after being disengaged from the MR, MUC1 goes on to be properly sorted and processed.
HER2/neu tumor Ag is similarly retained in early DC endosomes
Difficulty in intracellular trafficking and inefficient processing as causes of a diminished immune response to tumor Ags are not likely to be unique to MUC1. HER-2/neu is an oncogenic glycoprotein overexpressed by adenocarcinomas of the breast, ovary, stomach, uterus, and lung. Patients with HER-2/neu-expressing tumors demonstrate weak immune responses to HER-2/neu, including low titer Abs, limited T cell proliferative activity, and some CTL activity (56) . Interestingly, strong Th cell responses and Abs were elicited to this protein in a vaccination model in which rats were immunized with short synthetic peptides derived from the rat HER-2/neu sequence in Freund's adjuvant. In the same model, immunization with the full-length protein in adjuvant failed to elicit any immune response (30) . HER-2/neu protein contains numerous carbohydrates on its ECD. The ECD is shed from tumor cells and can be found in the serum of adenocarcinoma patients. We postulated that the glycosylated, soluble form of HER2/neu, much like MUC1, may not be properly trafficked by DC, resulting in the lack of processing for Th cell generation.
Our confocal microscopic analyses support this hypothesis by demonstrating that, like glycosylated tumor MUC1, HER-2/neu is retained in early endosomes and is not trafficked to MIIC compartments (Fig. 7) . For these experiments, DC were exogenously pulsed on chamber slides with glycosylated Cy5-labeled HER-2/ neu protein for 1 h, then washed and allowed to process the protein for an additional 1 h. The cells were fixed, permeabilized, and stained with PE-labeled Abs against markers of either early or late endosomes. In the top six panels of Fig. 7 , it is clear that HER-2/ neu was colocalized with the early endosomal markers, transferrin receptor, and MR. HER-2/neu was, however, not colocalized with late endosomal markers HLA-DR, HLA-DM, or LAMP-1, as demonstrated in the lower nine panels of Fig. 7 . HER-2/neu staining was proximal to the plasma membrane, with little or no protein present in perinuclear endosomes, showing the same hindered intracellular trafficking as that seen for MUC1.
Internalized glycosylated tumor MUC1 can recycle back to the cell surface and out of the cell
MR has been shown to recycle back to the plasma membrane after unloading its ligand in early endosomes (52) . Mannose and sucrose residues recognized by the MR on the glycosylated tumor MUC1 are positioned in a highly tandemly repeated array, possibly leading to a high avidity receptor-ligand cross-linking. We hypothesize that as a consequence of this interaction many MUC1 protein molecules will be unable to dissociate from MR in early endosomes and will be eventually recycled back (for possibly several rounds) to the cell surface where, at a different pH, some MUC1 molecules may ultimately detach and be released in the extracellular environment. To test this hypothesis we exposed the DC, following a 30-min pulse with Ag, to acidic conditions (0.15 M glycine, pH 4.0, for 30 min on ice), which favor the disruption of receptorligand interactions at the cell surface. Following the acid stripping of all ligand still on the cell surface, the cells were returned to physiologic conditions, for 90 min after which the cells were pelleted, and the supernatants were saved for detection by ELISA of internalized MUC1 molecules that were recycled back to the cell surface and detached from the receptors. Fig. 8 shows that following acid stripping, there was loss of fluorescence indicating loss of internalized Ag. There was an ϳ80% decrease in the MFI for the glycosylated tumor MUC1 (Fig. 8A ) and a 55% decrease for the MUC1 140-mer peptide (Fig. 8B) . The control FITC-conjugated mannosylated BSA (a ligand for the MR that dissociates in early endosomes) showed a decrease of only 35% (Fig. 8C) . We assayed the supernatants by ELISA for the presence of either surfacebound MUC1, released by acid treatment, or soluble MUC1, recycled from intracellular compartments (Fig. 8D) . We found greater amounts of released Ag in the case of glycosylated MUC1 compared with the MUC1 peptide. Furthermore, in the case of glycosylated MUC1, protein is clearly recycled back to the cell surface bound to the receptor. When the bound Ag is stripped off the receptor with acid treatment first, less MUC1 is detected in the supernatant. The acid treatment of DC did not affect their viability, as observed by forward-side scatter analysis on FACS.
We conclude that the early endosomal retention compartment in which the glycosylated tumor MUC1 protein may reside for long periods of time may actually be continuously renewed with molecules that recycle, with MR, from early endosomes to the plasma membrane and then back inside, with the protein being gradually lost into the extracellular environment over time (Fig. 9) .
Discussion
The role of protein glycosylation in the uptake, trafficking, and processing by APC is not well understood. There have been several reports describing inhibition of processing and presentation of bacterial Ags due to the presence of oligosaccharides (42, (57) (58) (59) (60) . In one report Th-independent type Ags (polysaccharides) inhibited presentation of KLH to class II MHC-restricted T cells by macrophages preincubated with several different carbohydrates (42) . The extent of inhibition depended both on the type of APC and on the chemical characteristics of the carbohydrates. In another report polysaccharides of Salmonella LPS were demonstrated to interfere with presentation of Salmonella Ags to T cells, but did not inhibit presentation of numerous other protein Ags (59) . Saccharide residues could also sterically interfere with the interaction of degradative intracellular proteases with the protein backbone of glycoproteins, impeding their degradation. In support of this hypothesis, extensive N-linked glycosylation is thought to protect resident lysosomal proteins (in particular LAMP1) from degradation in the hostile environment of the lysosome (60, 61) . Many of these mechanisms may influence how the tumor glycoprotein Ag MUC1 is handled by APC, and this, in turn, may determine the extent of an immune response generated. Glycosylation of tumor MUC1, made more complex by the tandem repeat structure of the protein, may interfere with its trafficking inside the APC as well as protect it from degradation by proteolytic enzymes.
Internalization of Ags through the MR typically results in at least a 100-fold increase in efficiency of presentation by class II MHC over uptake via macropinocytosis (45, 62) . In the case of MUC1, we show that binding and internalization via the MR do not deliver this Ag to the MIIC compartments. We propose that this is due to the exceptional avidity of binding of glycosylated MUC1 to MR via numerous tandemly repeated carbohydrates that does not allow dissociation from the receptor in the early endosomal sorting compartments (CURL). Therefore, MUC1 cannot be transported to later endosomal compartments for degradation and binding to class II MHC.
Long-term retention of Ag by immature DC has been also observed by other investigators (42) . It is thought that long-term retention of Ag internalized in tissues enables the immature DC to travel from peripheral locations to lymph nodes before degrading its internalized Ag. DC then process and present those Ags to T cells in the lymph node. The authors of this study employed a murine fetal skin-derived DC line exhibiting the characteristics of immature DC. In this model the endosomal compartment in which the Ag was retained was characterized as a class II-MHC rich compartment that also contained the lysosomal marker LAMP1 and cathepsin D. There are, however, significant differences between the long-term retention compartment identified in immature DC and the compartment in which glycosylated MUC1 is retained. The compartment in which MUC1 is stored contains no markers of late endosomes or class II MHC, only early endosomal markers. Therefore, it is unlikely that MUC1 is being stored by DC for later degradation, but instead, DC appear unable to properly sort and transport MUC1 to late endosomes and lysosomes for processing.
While much is known about MUC1 glycosylation, there is a lot less information about the specific sugar residues present on HER-2/neu ECD, and more will need to be done to completely understand its processing and presentation by DC. Our findings presented here on the similarity in intracellular trafficking of MUC1 and HER-2/neu do show, however, that in addition to MUC1, other tumor glycoproteins may be inefficiently handled by APCs, which is expected to result in the lack of presentation by class II MHC and failure to stimulate Th cells (63) .
Understanding how an Ag of interest is handled by the immune system, especially by APC at the priming step of the immune response, is critical for any effort directed toward manipulating the immune response against that Ag. In the case of MUC1, we now believe that the data presented here provide a reasonable explanation for our previously published observations that Th cell responses are not elicited against the soluble form of the Ag available either in vivo in the cancer patient or in vitro. We also know from studies presented here and from our previous studies (25, 26, 64) that we can overcome this problem by providing APCs with an unglycosylated synthetic form of MUC1. The long synthetic MUC1 peptide (100 aa) is currently in use in several cancer vaccine clinical trials. These complexes enter an early endosomal sorting compartment in which receptors and ligands are disengaged and segregated into separate compartments. Receptors are concentrated into tubular compartments, which are recycled to the cell surface, and concentrated protein ligand is transported to later endosomes, lysosomes, or MIIC for degradation and binding to class II MHC. Glycosylated MUC1 (left) binds and is internalized via the MR on DC. Due to the large number of tandemly repeated sugars along the protein backbone, the MR become extensively cross-linked, and the avidity of this interaction is so strong that the MR do not dissociate from the MUC1. As a result, the MR remain trapped in the early endosomes, and MUC1 cannot be transported to later endosomal compartments for processing. A fraction of the undissociated receptor-ligand complexes recycles back to the cell surface, where some glycosylated tumor MUC1 molecules are detached and released while others get internalized again.
